Stereotaxis, Inc. (Nasdaq: STXS) today announced that the U.S. Patent and Trademark Office granted the Company its 100th patent, a major intellectual property milestone. The 100th patent, U.S. patent No. 7,772,950, covers the "Method and Apparatus for Dynamic Magnetic Field Control Using Multiple Magnets." The 100th patent reflects Stereotaxis' ongoing commitment to innovate and protect its leading position in robotic solutions for interventional medicine.
"Our 100th patent represents a significant milestone in Stereotaxis' drive to protect shareholder value and deliver innovative technologies that improve treatment options for patients with cardiovascular disease," said Michael P. Kaminski, President and Chief Executive Officer. "Our strong intellectual property position enables the delivery of measurable clinical benefits across the broadest range of cardiovascular, neurovascular, peripheral vascular and other interventional applications, including treatment of ventricular tachycardia with high levels of acute success."
For more than 15 years, Stereotaxis has built a robust intellectual property portfolio, which includes these 100 issued patents and over 100 additional patent applications in process for approval. Stereotaxis' extensive U.S. patent portfolio is supplemented by more than 30 non-U.S. patents and patent applications. The Company anticipates doubling the number of non-U.S. patents in the next few months as patents issue on its Niobe® Magnetic Navigation System. The patents issued to date include remote/robotic assisted cardiology procedures, diagnostic integration, therapeutic devices, software automation, and information technology for patient/case management.
For the past two years, Stereotaxis ranked in the top 10 of IEEE Spectrum's Patent Power Scorecard, a rating of the world's most valuable patent portfolios. Many of Stereotaxis' 100 U.S. patents have been the basis for new product solutions, while others have been strategically leveraged in alliances with global giants in the area of cardiology.
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options